Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Shire Plc Ads (SHPG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 46,575,076
  • Shares Outstanding, K 300,310
  • Annual Sales, $ 11,397 M
  • Annual Income, $ 327,400 K
  • 36-Month Beta 1.61
  • Price/Sales 4.09
  • Price/Cash Flow 9.49
  • Price/Book 1.52

Price Performance

See More
Period Period Low Period High Performance
1-Month
141.74 +9.42%
on 08/24/17
162.64 -4.64%
on 09/12/17
+11.93 (+8.33%)
since 08/22/17
3-Month
139.36 +11.29%
on 08/21/17
174.67 -11.21%
on 06/26/17
-19.83 (-11.34%)
since 06/22/17
52-Week
139.36 +11.29%
on 08/21/17
204.31 -24.09%
on 09/23/16
-49.13 (-24.06%)
since 09/22/16

Most Recent Stories

More News
Is Shire plc (SHPG) a Suitable Value Stock?

Shire is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

SHPG : 155.09 (-0.17%)
Shire and Shionogi Announce Positive Topline Results for INTUNIV(R) Evaluated in Phase 3 Clinical Trial in Adults with ADHD

Shire and Shionogi Announce Positive Topline Results for INTUNIV(R) (guanfacine hydrochloride prolonged release) Evaluated in Phase 3 Clinical Trial

SHPG : 155.09 (-0.17%)
Supernus Drops SPN-810's Lower Dose Test in Phase III Trials

Supernus (SUPN) decides to stop evaluating the lower dose option of SPN-810 for treatment of impulsive aggression. However, the company will carry on with the study of higher dose arm or placebo.

SUPN : 39.00 (-1.02%)
SHPG : 155.09 (-0.17%)
ACAD : 37.59 (-0.11%)
ADRO : 10.80 (-1.82%)
Neos Therapeutics ADHD Drug Adzenys Receives Approval in US

Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.

JNJ : 131.39 (-0.27%)
SHPG : 155.09 (-0.17%)
PFE : 35.96 (-0.03%)
NEOS : 8.85 (-1.12%)
Smart Medical Device Could Save Millions of Lives

Stroke and heart diseases cost the U.S. nearly $1 billion every day in medical costs and lost productivity, so when a small-cap biotech company finally starts releasing validation news for a medical device...

EXAS : 45.96 (+2.13%)
CLBS : 3.80 (+0.26%)
SHPG : 155.09 (-0.17%)
REGN : 432.72 (-0.17%)
Top Research Reports for Disney, Kraft Heinz & CVS Health

Top Research Reports for Disney, Kraft Heinz & CVS Health

CVS : 79.63 (+0.09%)
VTR : 66.04 (-2.19%)
KHC : 77.52 (-1.89%)
SHPG : 155.09 (-0.17%)
ICE : 67.05 (+0.33%)
DIS : 98.60 (-0.29%)
Shire Receives FDA Fast Track Designation for SHP607 for the Prevention of Chronic Lung Disease in Extremely Premature Infants

Shire Receives FDA Fast Track Designation for SHP607 for the Prevention of Chronic Lung Disease in Extremely Premature Infants

SHPG : 155.09 (-0.17%)
Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial

Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal...

SHPG : 155.09 (-0.17%)
Daily Technical Summary Reports on Healthcare Stocks -- Shire, Aerie Pharma, Heron Therapeutics, and United Therapeutics

If you want a Stock Review on SHPG, AERI, HRTX, or UTHR then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com has investors'...

AERI : 50.95 (-0.97%)
SHPG : 155.09 (-0.17%)
UTHR : 114.60 (-0.74%)
HRTX : 15.20 (+0.33%)
Alnylam Shares Plunge on Patient Death, Dosing Suspended

Alnylam (ALNY) announced suspension of dosing in all ongoing studies on its hemophilia candidate, fitusiran, following a patient's death in a phase II study.

LGND : 135.55 (-0.19%)
ALNY : 113.80 (+0.78%)
SHPG : 155.09 (-0.17%)
SNY : 50.34 (+0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)

See More

Support & Resistance

2nd Resistance Point 158.31
1st Resistance Point 156.70
Last Price 155.09
1st Support Level 153.94
2nd Support Level 152.79

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.